EGFR and non-small cell lung carcinoma: EGFR-tyrosine kinase inhibitors (TKIs) are a class of drugs that specifically target the EGFR tyrosine kinase activity, showing significant clinical efficacy, and they are now considered as the standard of care for NSCLC patients with EGFR mutations [120,121,122,123].